- Home
- BCAL vs ALDX Comparison
BCAL vs ALDX Comparison
Compare BCAL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAL
- ALDX
- Stock Information
- Founded
- BCAL 2001
- ALDX 2004
- Country
- BCAL United States
- ALDX United States
- Employees
- BCAL N/A
- ALDX N/A
- Industry
- BCAL Major Banks
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAL Finance
- ALDX Health Care
- Exchange
- BCAL Nasdaq
- ALDX Nasdaq
- Market Cap
- BCAL 451.9M
- ALDX 343.5M
- IPO Year
- BCAL N/A
- ALDX 2014
- Fundamental
- Price
- BCAL $14.43
- ALDX $5.55
- Analyst Decision
- BCAL Hold
- ALDX Strong Buy
- Analyst Count
- BCAL 1
- ALDX 4
- Target Price
- BCAL N/A
- ALDX $9.33
- AVG Volume (30 Days)
- BCAL 59.7K
- ALDX 452.1K
- Earning Date
- BCAL 10-24-2024
- ALDX 11-01-2024
- Dividend Yield
- BCAL N/A
- ALDX N/A
- EPS Growth
- BCAL N/A
- ALDX N/A
- EPS
- BCAL 0.86
- ALDX N/A
- Revenue
- BCAL $87,326,000.00
- ALDX N/A
- Revenue This Year
- BCAL N/A
- ALDX N/A
- Revenue Next Year
- BCAL $48.98
- ALDX $25.36
- P/E Ratio
- BCAL $16.81
- ALDX N/A
- Revenue Growth
- BCAL N/A
- ALDX N/A
- 52 Week Low
- BCAL $12.30
- ALDX $1.46
- 52 Week High
- BCAL $18.00
- ALDX $6.55
- Technical
- Relative Strength Index (RSI)
- BCAL 53.58
- ALDX 54.14
- Support Level
- BCAL $13.65
- ALDX $5.28
- Resistance Level
- BCAL $14.04
- ALDX $5.37
- Average True Range (ATR)
- BCAL 0.32
- ALDX 0.24
- MACD
- BCAL 0.03
- ALDX 0.01
- Stochastic Oscillator
- BCAL 61.90
- ALDX 77.61
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through strong partnerships with its clients.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.